GlassScriptPhysician profile
Jennifer Muller
NPI 1790763985
$13,095.06
in general payments reported to CMS, 2019-2025
69 companies · $2,914 in 2025
The $2,914 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $404 · 2021: $1,594 · 2022: $1,465 · 2023: $3,309 · 2024: $3,262 · 2025: $2,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,049 · Travel and Lodging: $246 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,048.85 |
| Travel and Lodging | $246.08 |
| Education | $190.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,327.53 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $987.27 | 2020-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $837.60 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Incyte Corporation | $686.14 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $651.91 | 2021-2025 | Trodelvy |
| Pfizer INC. | $643.62 | 2020-2025 | |
| Janssen Biotech, INC. | $629.86 | 2019-2025 | Darzalex, Talvey, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $553.01 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Celgene Corporation | $472.55 | 2020-2025 | Reblozyl, Opdualag, Pomalyst |
| Glaxosmithkline, LLC. | $355.12 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Beigene USA, INC. | $339.87 | 2020-2024 | Brukinsa, Tevimbra |
| Lilly USA, LLC | $286.94 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $280.09 | 2020-2025 | |
| Seagen INC. | $265.87 | 2020-2023 | Adcetris, Tukysa, Padcev |
| Intuitive Surgical, INC. | $246.08 | 2023 | Da Vinci Surgical System |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $239.26 | 2021-2025 | Ninlaro, Alunbrig, Iclusig |
| Eisai INC. | $239.06 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $237.33 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $232.53 | 2020-2025 | Polivy, Lunsumio, Alecensa |
| Myriad Genetic Laboratories, INC. | $215.92 | 2022-2025 | Mychoice Cdx, Myrisk |
| Abbvie INC. | $202.59 | 2020-2025 | |
| Array Biopharma INC | $190.31 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Taiho Oncology, INC. | $179.46 | 2023-2025 | |
| Genzyme Corporation | $176.01 | 2019-2025 | |
| Exelixis INC. | $173.84 | 2023-2025 | Cabometyx |
| Astellas Pharma US INC | $149.28 | 2021-2025 | Vyloy, Padcev |
| Beone Medicines USA, INC. | $148.27 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $143.76 | 2021-2025 | Enhertu, Datroway |
| Alexion Pharmaceuticals, INC. | $128.45 | 2021-2024 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $124.55 | 2025 | |
| Sobi, INC | $97.95 | 2022-2025 | |
| Kyowa Kirin, INC. | $97.18 | 2021-2024 | Poteligeo |
| Rigel Pharmaceuticals, INC. | $85.21 | 2023-2024 | Rezlidhia, Tavalisse |
| Deciphera Pharmaceuticals INC. | $84.38 | 2021 | |
| Dova Pharmaceuticals | $83.92 | 2021 | |
| Amgen INC. | $82.65 | 2021-2023 | Lumakras |
| Tersera Therapeutics LLC | $82.29 | 2024-2025 | Zoladex |
| Apellis Pharmaceuticals, INC. | $76.42 | 2023-2025 | Empaveli |
| Genmab U.S., INC. | $72.41 | 2023-2025 | Epkinly |
| Kite Pharma, INC. | $69.67 | 2023-2025 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.21 | 2021-2024 | Gilotrif |
| Morphosys, US INC. | $57.78 | 2023 | Monjuvi |
| Jazz Pharmaceuticals INC. | $53.88 | 2021-2023 | Zepzelca |
| Mirati Therapeutics, INC. | $53.58 | 2023-2024 | Krazati |
| Geron Corporation | $50.84 | 2025 | Rytelo |
| Emd Serono, INC. | $50.39 | 2024-2025 | |
| Stemline Therapeutics INC. | $47.17 | 2023-2024 | Orserdu |
| Puma Biotechnology, INC. | $45.40 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $43.64 | 2023 | Imbruvica, Epkinly |
| Tempus Ai, INC | $39.08 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $32.97 | 2019-2022 | |
| Agios Pharmaceuticals, INC. | $32.81 | 2023-2024 | Pyrukynd |
| Adc Therapeutics America, INC. | $32.72 | 2022-2023 | |
| Aveo Pharmaceuticals, INC. | $30.97 | 2023-2025 | Fotivda |
| Ge Healthcare | $26.75 | 2022 | |
| Pharmaessentia USA Corporation | $24.36 | 2024 | Besremi |
| Acrotech Biopharma INC. | $23.34 | 2022 | |
| Karyopharm Therapeutics INC. | $22.94 | 2025 | Xpovio |
| Alnylam Pharmaceuticals INC. | $22.64 | 2023 | Onpattro |
| Janssen Pharmaceuticals, INC | $20.40 | 2023 | Xarelto |
| Recordati_rare_diseases_inc. | $19.50 | 2025 | Enjaymo |
| Dendreon Pharmaceuticals LLC | $18.56 | 2022 | |
| Cti Biopharma Corp. | $16.90 | 2023 | Vonjo |
| G1 Therapeutics, INC. | $16.89 | 2023 | Cosela |
| Sirtex Medical INC | $16.86 | 2020 | |
| Acceleron Pharma, INC. | $16.75 | 2020 | |
| Amag Pharmaceuticals, INC. | $16.69 | 2021 | |
| Emmaus Medical, INC. | $14.21 | 2021 | |
| Advanced Accelerator Applications | $12.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Muller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.